CMS (Centers for Medicare and Medicaid Services, which runs Medicare) or a major insurance company announces they will pay for psilocybin or MDMA therapy. This would be huge for patients and companies. But it almost won't happen in six months because the FDA hasn't approved any psychedelic medicine yet, and insurers won't pay for unapproved drugs.
No psychedelic-assisted therapy is currently FDA-approved in the U.S. (MDMA was rejected; psilocybin has no NDA). Without an approved product, CMS and private insurers have no regulatory basis for coverage guidance. 'Pilot program' or 'guidance' must be a formal, public, binding or semi-binding document—not a white paper or industry working group output. The six-month window is almost certainly too short given the approval gap. Confidence reduced substantially from original 0.65; the premise requires an FDA approval that does not yet exist.